AbbVie snaps eight straight sessions of losses
by
Contributor since / Followers
Contributor since / Followers
3 days ago
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) shares snapped eight consecutive sessions of losses as
ABBV
Aldeyra announces FDA acceptance of resubmitted reproxalap application
by
Contributor since / Followers
Contributor since / Followers
3 days ago
hapabapa Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular
AbbVie shares trade in the red for seventh straight session
by
Contributor since / Followers
Contributor since / Followers
7 days ago
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) shares traded in the red on Thursday, making
Bristol-Myers upgraded at Leerink after AbbVie setback
by
Contributor since / Followers
Contributor since / Followers
1 week ago
hapabapa/iStock Editorial via Getty Images Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market
Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)
by Bradley Guichard
Contributor since 2021 / 9787 Followers
Contributor since 2021 / 9787 Followers
1 week ago
Summary: AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting
AbbVie Stock: Keep Calm And Buy The Dip
by Kumquat Research
Contributor since 2014 / 12543 Followers
Contributor since 2014 / 12543 Followers
1 week ago
Summary: AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials.
How AbbVie can still benefit from Cerevel acquisition despite emraclidine setback
by
Contributor since / Followers
Contributor since / Followers
1 week ago
Michael Vi/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) and its shareholders were dealt a major
AbbVie: Emraclidine’s Failure Eliminates An Important Growth Driver
by ONeil Trader
Contributor since 2012 / 8762 Followers
Contributor since 2012 / 8762 Followers
1 week ago
Summary: Emraclidine’s failure in phase 2 trials is a significant setback for AbbVie’s neuroscience pipeline.
AbbVie declines after missing main goal in schizophrenia treatment trials
by
Contributor since / Followers
Contributor since / Followers
1 week ago
hapabapa AbbVie (NYSE:ABBV) shares dropped about 11% after its late-stage trials investigating emraclidine as an
8 High-momentum stocks set for success – Oppenheimer
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
Easyturn/iStock via Getty Images Momentum is currently a key factor when investing, according to Oppenheimer